ERBB2 and ovarian cancer: designed and encapsulated anticancer dual HSP27 and HER2 inhibitors into low-density lipoprotein to target the SKOV3 ovarian cancer cell line and the IC50 results were in the 22.5 μM level (Alhadad et al., 2020).